SOPHiA GENETICS SA
SOPHiA GENETICS was founded to generate clinically actionable insights from data to improve patient outcomes. Our mission is to provide equal access to knowledge and capabilities by democratizing data-driven medicine.
We observed that across the healthcare ecosystem, a vast amount of digital healthcare data was being generated, fueled by technologies such as NGS (next-generation sequencing), and which held promise to accelerate the understanding of biology and disease. However, this data has been generated primarily using non-standardized methods and by clinicians and researchers across many healthcare institutions. As a result, the data remained siloed and complex and was not fully leveraged for the benefit of patients.
We built a cloud-based software-as-a-service (“SaaS”) platform capable of analyzing data and generating insights from complex multimodal data sets and different diagnostic modalities. Our platform standardizes, computes and analyzes digital health data and is used across decentralized locations to break down data silos. This enables healthcare institutions to share knowledge and experiences and to build a collective intelligence. We envision a future in which all clinical diagnostic test data is channeled through a decentralized analytics platform that will provide insights powered by large real-world data sets and AI.
(Note: Sophia Genetics priced its IPO on July 22, 2021, at $18 – the mid-point of its $17-to-$19 range – on 13 million shares, the same number of shares in the prospectus, to raise $234 million.)
(Note: On its first day of trading on July 23, 2021, Sophia Genetics’ stock opened at $18.45, hit an intraday high of $18.74, and closed at $16.76.)
|Industry:||BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES)|
|Address||Rue du Centre 172 CH-1025 Saint-Sulpice Switzerland|
|Phone Number||+ 41 21 694 10 60|
|View Prospectus:||SOPHiA GENETICS SA|
|Revenues||$29.9 mil (last 12 months)|
|Net Income||$-41.5 mil (last 12 months)|
|Price range||$18.00 - $18.00|
|Est. $ Volume||$234.0 mil|
|Manager / Joint Managers||J.P. Morgan/ Morgan Stanley/ Cowen and Company/ Credit Suisse|
|Expected To Trade:||7/23/2021|
|Quiet Period Expiration Date:||Available only to Subscribers|
|Lock-Up Period Expiration Date:||Available only to Subscribers|
|SCOOP Rating||Available only to Subscribers|
|Rating Change||Available only to Subscribers|